 Nicholas Cost
Concepts (396)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 66 | 2025 | 403 | 16.930 |
Why?
| | Wilms Tumor | 36 | 2025 | 86 | 11.130 |
Why?
| | Testicular Neoplasms | 23 | 2023 | 110 | 9.110 |
Why?
| | Nephrectomy | 35 | 2025 | 169 | 6.500 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 14 | 2023 | 77 | 5.980 |
Why?
| | Lymph Node Excision | 13 | 2024 | 171 | 4.080 |
Why?
| | Carcinoma, Renal Cell | 18 | 2025 | 217 | 4.010 |
Why?
| | Rhabdoid Tumor | 6 | 2025 | 99 | 2.920 |
Why?
| | Lymph Nodes | 9 | 2023 | 491 | 2.630 |
Why?
| | Neoplasm Staging | 25 | 2023 | 1389 | 2.430 |
Why?
| | Urology | 8 | 2024 | 63 | 2.380 |
Why?
| | Child | 99 | 2025 | 21935 | 2.250 |
Why?
| | Urinary Bladder | 5 | 2024 | 183 | 2.210 |
Why?
| | Medical Oncology | 7 | 2023 | 289 | 2.200 |
Why?
| | Lower Urinary Tract Symptoms | 3 | 2025 | 60 | 2.120 |
Why?
| | Child, Preschool | 68 | 2025 | 11074 | 2.060 |
Why?
| | Orchiectomy | 8 | 2023 | 71 | 2.010 |
Why?
| | Urodynamics | 4 | 2025 | 44 | 2.000 |
Why?
| | Laparoscopy | 12 | 2024 | 466 | 1.980 |
Why?
| | Rhabdomyosarcoma | 5 | 2022 | 72 | 1.840 |
Why?
| | Hydronephrosis | 6 | 2019 | 36 | 1.840 |
Why?
| | Adolescent | 71 | 2025 | 21513 | 1.810 |
Why?
| | Urinary Tract | 3 | 2025 | 51 | 1.800 |
Why?
| | Infant | 58 | 2025 | 9465 | 1.790 |
Why?
| | Vincristine | 3 | 2024 | 116 | 1.730 |
Why?
| | Lymphatic Metastasis | 12 | 2022 | 352 | 1.620 |
Why?
| | Urologic Surgical Procedures | 8 | 2019 | 120 | 1.610 |
Why?
| | Urologists | 3 | 2017 | 17 | 1.600 |
Why?
| | Urologic Neoplasms | 4 | 2017 | 31 | 1.520 |
Why?
| | Radiotherapy | 2 | 2025 | 201 | 1.490 |
Why?
| | Male | 106 | 2025 | 67762 | 1.470 |
Why?
| | Humans | 156 | 2025 | 137585 | 1.460 |
Why?
| | Kidney Pelvis | 6 | 2015 | 24 | 1.420 |
Why?
| | Robotics | 6 | 2015 | 94 | 1.400 |
Why?
| | Pelvic Neoplasms | 3 | 2025 | 26 | 1.400 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 89 | 1.390 |
Why?
| | Prognosis | 24 | 2025 | 4030 | 1.320 |
Why?
| | Pediatrics | 7 | 2025 | 1101 | 1.320 |
Why?
| | Practice Patterns, Physicians' | 6 | 2024 | 1313 | 1.320 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2021 | 252 | 1.230 |
Why?
| | Organ Sparing Treatments | 4 | 2023 | 34 | 1.200 |
Why?
| | Doxorubicin | 2 | 2021 | 362 | 1.160 |
Why?
| | Ureteral Obstruction | 5 | 2015 | 64 | 1.110 |
Why?
| | Urinary Bladder Diseases | 2 | 2019 | 19 | 1.100 |
Why?
| | Kidney | 9 | 2023 | 1468 | 1.090 |
Why?
| | Retrospective Studies | 47 | 2025 | 15657 | 1.060 |
Why?
| | Female | 83 | 2025 | 73304 | 1.040 |
Why?
| | Tumor Burden | 6 | 2019 | 309 | 0.990 |
Why?
| | Young Adult | 33 | 2025 | 13209 | 0.930 |
Why?
| | Kidney Diseases, Cystic | 3 | 2021 | 24 | 0.930 |
Why?
| | Rhabdomyosarcoma, Embryonal | 2 | 2022 | 22 | 0.920 |
Why?
| | Nephrons | 9 | 2023 | 18 | 0.910 |
Why?
| | Biopsy | 6 | 2024 | 1129 | 0.870 |
Why?
| | Ribonuclease III | 3 | 2021 | 40 | 0.870 |
Why?
| | Sarcoma, Clear Cell | 3 | 2025 | 10 | 0.850 |
Why?
| | Mixed Tumor, Malignant | 1 | 2023 | 5 | 0.850 |
Why?
| | DEAD-box RNA Helicases | 3 | 2021 | 76 | 0.840 |
Why?
| | Surgeons | 4 | 2025 | 297 | 0.840 |
Why?
| | Sertoli-Leydig Cell Tumor | 3 | 2021 | 8 | 0.840 |
Why?
| | Hypospadias | 4 | 2011 | 29 | 0.810 |
Why?
| | Seminoma | 3 | 2021 | 20 | 0.800 |
Why?
| | Sarcoma | 3 | 2024 | 188 | 0.780 |
Why?
| | Urologic Surgical Procedures, Male | 4 | 2018 | 30 | 0.780 |
Why?
| | Spermatic Cord Torsion | 2 | 2013 | 4 | 0.770 |
Why?
| | Leydig Cell Tumor | 3 | 2021 | 8 | 0.770 |
Why?
| | Disease-Free Survival | 7 | 2022 | 686 | 0.750 |
Why?
| | Surgical Oncology | 2 | 2025 | 27 | 0.740 |
Why?
| | Paraganglioma | 1 | 2022 | 52 | 0.740 |
Why?
| | Cryptorchidism | 2 | 2019 | 15 | 0.730 |
Why?
| | Age Factors | 12 | 2019 | 3295 | 0.710 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.710 |
Why?
| | Neoplasms | 7 | 2025 | 2671 | 0.700 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 128 | 0.700 |
Why?
| | Pheochromocytoma | 2 | 2019 | 59 | 0.690 |
Why?
| | Tomography, X-Ray Computed | 9 | 2021 | 2691 | 0.680 |
Why?
| | Molecular Targeted Therapy | 3 | 2025 | 411 | 0.660 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2024 | 1079 | 0.660 |
Why?
| | Follow-Up Studies | 18 | 2025 | 5131 | 0.660 |
Why?
| | Infant, Newborn | 11 | 2023 | 6079 | 0.650 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 4 | 0.650 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 2 | 2017 | 5 | 0.630 |
Why?
| | Cystectomy | 1 | 2019 | 37 | 0.630 |
Why?
| | Smooth Muscle Myosins | 1 | 2019 | 6 | 0.630 |
Why?
| | Muscle Relaxation | 1 | 2019 | 19 | 0.620 |
Why?
| | Myosin Light Chains | 1 | 2019 | 26 | 0.620 |
Why?
| | Neoplasm Invasiveness | 7 | 2017 | 510 | 0.620 |
Why?
| | Treatment Outcome | 27 | 2025 | 10811 | 0.610 |
Why?
| | Retroperitoneal Space | 2 | 2024 | 20 | 0.600 |
Why?
| | Fertility Preservation | 3 | 2024 | 49 | 0.600 |
Why?
| | Diagnostic Imaging | 3 | 2022 | 332 | 0.600 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 5778 | 0.590 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 127 | 0.590 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 52 | 0.590 |
Why?
| | Neoadjuvant Therapy | 4 | 2021 | 404 | 0.580 |
Why?
| | Catheterization | 1 | 2019 | 179 | 0.580 |
Why?
| | von Hippel-Lindau Disease | 1 | 2018 | 12 | 0.580 |
Why?
| | Testicular Diseases | 1 | 2018 | 7 | 0.580 |
Why?
| | Specimen Handling | 1 | 2019 | 183 | 0.570 |
Why?
| | Health Care Surveys | 2 | 2017 | 565 | 0.570 |
Why?
| | Calculi | 1 | 2018 | 16 | 0.560 |
Why?
| | Risk Assessment | 11 | 2025 | 3457 | 0.550 |
Why?
| | Orchiopexy | 3 | 2019 | 6 | 0.550 |
Why?
| | Conservative Treatment | 1 | 2018 | 33 | 0.550 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 528 | 0.550 |
Why?
| | Kaplan-Meier Estimate | 6 | 2019 | 889 | 0.540 |
Why?
| | Radiation Exposure | 1 | 2017 | 49 | 0.540 |
Why?
| | Critical Pathways | 1 | 2018 | 96 | 0.530 |
Why?
| | Cytodiagnosis | 1 | 2017 | 33 | 0.530 |
Why?
| | Frozen Sections | 1 | 2017 | 26 | 0.530 |
Why?
| | Kidney Medulla | 1 | 2016 | 35 | 0.530 |
Why?
| | Angiomyolipoma | 1 | 2016 | 24 | 0.520 |
Why?
| | Survival Rate | 10 | 2025 | 1972 | 0.510 |
Why?
| | Cancer Survivors | 1 | 2021 | 285 | 0.510 |
Why?
| | Postoperative Care | 1 | 2018 | 261 | 0.510 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2526 | 0.510 |
Why?
| | Teratoma | 2 | 2017 | 114 | 0.500 |
Why?
| | Muscle Contraction | 1 | 2019 | 424 | 0.500 |
Why?
| | Robotic Surgical Procedures | 2 | 2015 | 130 | 0.490 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 55 | 0.490 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 13 | 0.490 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1692 | 0.480 |
Why?
| | Survival Analysis | 5 | 2019 | 1325 | 0.470 |
Why?
| | Pediatricians | 1 | 2016 | 129 | 0.460 |
Why?
| | Abdominal Neoplasms | 2 | 2025 | 39 | 0.460 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 746 | 0.460 |
Why?
| | Adult | 24 | 2025 | 37929 | 0.460 |
Why?
| | Prospective Studies | 11 | 2025 | 7604 | 0.450 |
Why?
| | Neurofibromatosis 1 | 2 | 2019 | 52 | 0.450 |
Why?
| | Societies, Medical | 5 | 2025 | 820 | 0.440 |
Why?
| | Adenoma | 1 | 2016 | 230 | 0.440 |
Why?
| | Cause of Death | 1 | 2016 | 434 | 0.430 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2012 | 2189 | 0.430 |
Why?
| | Prostatic Neoplasms | 2 | 2019 | 1043 | 0.420 |
Why?
| | Germ-Line Mutation | 3 | 2025 | 172 | 0.410 |
Why?
| | Acute-Phase Proteins | 1 | 2013 | 67 | 0.410 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2025 | 179 | 0.410 |
Why?
| | Lipocalins | 1 | 2013 | 36 | 0.410 |
Why?
| | Hypertension | 1 | 2022 | 1295 | 0.410 |
Why?
| | Databases, Factual | 5 | 2019 | 1357 | 0.410 |
Why?
| | Ultrasonography | 5 | 2019 | 759 | 0.410 |
Why?
| | Ovarian Neoplasms | 3 | 2021 | 565 | 0.400 |
Why?
| | Radiation Protection | 1 | 2013 | 38 | 0.400 |
Why?
| | Infertility | 2 | 2024 | 55 | 0.400 |
Why?
| | SEER Program | 5 | 2019 | 227 | 0.400 |
Why?
| | Patient Education as Topic | 1 | 2018 | 766 | 0.400 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2013 | 92 | 0.390 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 463 | 0.390 |
Why?
| | Combined Modality Therapy | 5 | 2025 | 1236 | 0.390 |
Why?
| | Biopsy, Needle | 1 | 2013 | 189 | 0.380 |
Why?
| | Multimodal Imaging | 1 | 2013 | 113 | 0.370 |
Why?
| | Glucose Transporter Type 1 | 1 | 2012 | 50 | 0.370 |
Why?
| | Carcinoma, Medullary | 2 | 2025 | 17 | 0.370 |
Why?
| | Primary Prevention | 1 | 2013 | 196 | 0.360 |
Why?
| | Multivariate Analysis | 5 | 2018 | 1509 | 0.360 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 658 | 0.360 |
Why?
| | Incidence | 7 | 2019 | 2804 | 0.360 |
Why?
| | Codon | 1 | 2011 | 89 | 0.350 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 294 | 0.350 |
Why?
| | United States | 13 | 2024 | 14841 | 0.350 |
Why?
| | Proline | 1 | 2011 | 79 | 0.350 |
Why?
| | Vena Cava, Inferior | 1 | 2011 | 71 | 0.340 |
Why?
| | Suburethral Slings | 1 | 2010 | 6 | 0.340 |
Why?
| | Seasons | 1 | 2013 | 547 | 0.330 |
Why?
| | Temperature | 1 | 2013 | 679 | 0.320 |
Why?
| | Hernia, Ventral | 1 | 2010 | 24 | 0.320 |
Why?
| | Sex Factors | 3 | 2024 | 2071 | 0.320 |
Why?
| | Arginine | 1 | 2011 | 271 | 0.320 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2010 | 38 | 0.320 |
Why?
| | Urinary Incontinence | 1 | 2010 | 66 | 0.320 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 648 | 0.320 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2253 | 0.310 |
Why?
| | Mouth Mucosa | 1 | 2009 | 92 | 0.310 |
Why?
| | Ureter | 4 | 2014 | 36 | 0.310 |
Why?
| | Campomelic Dysplasia | 1 | 2009 | 2 | 0.310 |
Why?
| | Length of Stay | 4 | 2025 | 1215 | 0.310 |
Why?
| | Dysgerminoma | 1 | 2009 | 6 | 0.310 |
Why?
| | Angiogenesis Inhibitors | 1 | 2011 | 229 | 0.310 |
Why?
| | Skin Transplantation | 1 | 2009 | 85 | 0.310 |
Why?
| | Urethra | 2 | 2011 | 55 | 0.310 |
Why?
| | Recovery of Function | 1 | 2013 | 653 | 0.310 |
Why?
| | Urolithiasis | 1 | 2009 | 9 | 0.310 |
Why?
| | Clitoris | 1 | 2009 | 9 | 0.300 |
Why?
| | SOX9 Transcription Factor | 1 | 2009 | 24 | 0.300 |
Why?
| | Brachytherapy | 2 | 2021 | 121 | 0.300 |
Why?
| | Bone Neoplasms | 1 | 2011 | 247 | 0.300 |
Why?
| | Venous Thrombosis | 1 | 2011 | 190 | 0.300 |
Why?
| | Attitude of Health Personnel | 1 | 2016 | 1171 | 0.290 |
Why?
| | Surgical Flaps | 1 | 2009 | 130 | 0.290 |
Why?
| | Time Factors | 8 | 2019 | 6828 | 0.290 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 815 | 0.280 |
Why?
| | Aged | 11 | 2021 | 23961 | 0.270 |
Why?
| | Neuroblastoma | 2 | 2025 | 160 | 0.270 |
Why?
| | Calcinosis | 1 | 2009 | 235 | 0.260 |
Why?
| | Health Promotion | 1 | 2013 | 741 | 0.260 |
Why?
| | Middle Aged | 13 | 2025 | 33479 | 0.260 |
Why?
| | Risk Factors | 8 | 2018 | 10388 | 0.260 |
Why?
| | Postoperative Complications | 6 | 2025 | 2654 | 0.250 |
Why?
| | Ureterocele | 2 | 2016 | 7 | 0.240 |
Why?
| | Vesico-Ureteral Reflux | 2 | 2016 | 32 | 0.240 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1276 | 0.230 |
Why?
| | Mitotic Index | 2 | 2015 | 25 | 0.230 |
Why?
| | Perioperative Care | 2 | 2024 | 178 | 0.230 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 916 | 0.230 |
Why?
| | Kidney Diseases | 1 | 2009 | 408 | 0.230 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2129 | 0.220 |
Why?
| | Hypertrophy | 2 | 2019 | 133 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2025 | 2426 | 0.220 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2013 | 389 | 0.220 |
Why?
| | Clinical Competence | 2 | 2025 | 1118 | 0.220 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2024 | 63 | 0.210 |
Why?
| | Gonadal Dysgenesis | 1 | 2023 | 7 | 0.210 |
Why?
| | Adrenocortical Carcinoma | 1 | 2024 | 65 | 0.210 |
Why?
| | Mast Cells | 1 | 2024 | 147 | 0.200 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2024 | 191 | 0.200 |
Why?
| | Lymphocytes | 1 | 2025 | 397 | 0.200 |
Why?
| | Tumor Suppressor Proteins | 1 | 2025 | 327 | 0.200 |
Why?
| | Pubic Bone | 1 | 2022 | 6 | 0.190 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2025 | 430 | 0.190 |
Why?
| | Monocytes | 1 | 2025 | 563 | 0.190 |
Why?
| | Urination | 1 | 2022 | 45 | 0.190 |
Why?
| | Algorithms | 1 | 2009 | 1704 | 0.180 |
Why?
| | Blood Platelets | 1 | 2025 | 408 | 0.180 |
Why?
| | Sertoli Cell Tumor | 1 | 2021 | 2 | 0.180 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2022 | 115 | 0.180 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 25 | 0.180 |
Why?
| | Aniridia | 1 | 2020 | 5 | 0.170 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1483 | 0.170 |
Why?
| | PAX6 Transcription Factor | 1 | 2020 | 21 | 0.170 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2019 | 98 | 0.170 |
Why?
| | Testosterone | 2 | 2015 | 409 | 0.170 |
Why?
| | Reoperation | 3 | 2014 | 573 | 0.170 |
Why?
| | Pneumothorax | 1 | 2021 | 38 | 0.170 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 44 | 0.170 |
Why?
| | Codon, Nonsense | 1 | 2020 | 44 | 0.170 |
Why?
| | Interleukin-2 | 1 | 2022 | 455 | 0.170 |
Why?
| | Eye Proteins | 1 | 2020 | 92 | 0.170 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1050 | 0.170 |
Why?
| | Syndrome | 1 | 2021 | 358 | 0.160 |
Why?
| | Penile Neoplasms | 1 | 2019 | 7 | 0.160 |
Why?
| | Priapism | 1 | 2019 | 11 | 0.160 |
Why?
| | Patient Selection | 3 | 2013 | 696 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 2057 | 0.160 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 43 | 0.160 |
Why?
| | Proportional Hazards Models | 3 | 2011 | 1266 | 0.160 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2019 | 8 | 0.160 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2019 | 20 | 0.160 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2019 | 10 | 0.160 |
Why?
| | Neutrophils | 1 | 2025 | 1238 | 0.150 |
Why?
| | Computers | 1 | 2019 | 70 | 0.150 |
Why?
| | Puberty, Precocious | 1 | 2019 | 13 | 0.150 |
Why?
| | Decision Trees | 1 | 2019 | 93 | 0.150 |
Why?
| | Dermatofibrosarcoma | 1 | 2018 | 9 | 0.150 |
Why?
| | Genotype | 2 | 2016 | 1916 | 0.150 |
Why?
| | Hospitals | 1 | 2023 | 691 | 0.150 |
Why?
| | Genetic Testing | 2 | 2019 | 460 | 0.150 |
Why?
| | Diagnostic Errors | 1 | 2019 | 170 | 0.150 |
Why?
| | Self-Examination | 1 | 2018 | 2 | 0.140 |
Why?
| | Proton Therapy | 1 | 2018 | 13 | 0.140 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 225 | 0.140 |
Why?
| | Animals | 6 | 2025 | 36940 | 0.140 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 160 | 0.140 |
Why?
| | Aged, 80 and over | 4 | 2019 | 7635 | 0.140 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 220 | 0.140 |
Why?
| | Preoperative Period | 1 | 2018 | 129 | 0.140 |
Why?
| | Mutation | 1 | 2009 | 3958 | 0.140 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.140 |
Why?
| | General Surgery | 1 | 2019 | 173 | 0.140 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 89 | 0.140 |
Why?
| | Analysis of Variance | 2 | 2017 | 1316 | 0.140 |
Why?
| | Unnecessary Procedures | 1 | 2017 | 50 | 0.140 |
Why?
| | Testis | 1 | 2018 | 151 | 0.130 |
Why?
| | Ultrasonography, Doppler | 1 | 2018 | 124 | 0.130 |
Why?
| | Intraoperative Period | 1 | 2017 | 59 | 0.130 |
Why?
| | Europe | 1 | 2018 | 414 | 0.130 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1329 | 0.130 |
Why?
| | Mice | 3 | 2024 | 17787 | 0.130 |
Why?
| | Feasibility Studies | 2 | 2018 | 956 | 0.130 |
Why?
| | Logistic Models | 3 | 2018 | 2074 | 0.130 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1272 | 0.130 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 416 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 306 | 0.120 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.120 |
Why?
| | North America | 1 | 2016 | 313 | 0.120 |
Why?
| | Certification | 1 | 2016 | 113 | 0.120 |
Why?
| | Translocation, Genetic | 2 | 2018 | 105 | 0.120 |
Why?
| | Learning | 1 | 2019 | 409 | 0.120 |
Why?
| | Models, Statistical | 1 | 2019 | 669 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1587 | 0.110 |
Why?
| | History, 21st Century | 1 | 2015 | 213 | 0.110 |
Why?
| | Phosphorylation | 1 | 2019 | 1759 | 0.110 |
Why?
| | Anaplasia | 2 | 2024 | 6 | 0.110 |
Why?
| | Matched-Pair Analysis | 1 | 2014 | 39 | 0.110 |
Why?
| | Forecasting | 1 | 2016 | 389 | 0.110 |
Why?
| | Registries | 2 | 2019 | 2035 | 0.110 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2014 | 17 | 0.110 |
Why?
| | Genitalia, Female | 1 | 2014 | 38 | 0.110 |
Why?
| | Ureteral Calculi | 1 | 2014 | 14 | 0.110 |
Why?
| | TRPM Cation Channels | 1 | 2014 | 74 | 0.110 |
Why?
| | Inflammation | 1 | 2025 | 2837 | 0.110 |
Why?
| | Kidney Function Tests | 1 | 2014 | 160 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 431 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3566 | 0.100 |
Why?
| | Disease Management | 1 | 2017 | 628 | 0.100 |
Why?
| | Lipocalin-2 | 1 | 2013 | 79 | 0.100 |
Why?
| | Estrogens | 1 | 2015 | 367 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 951 | 0.100 |
Why?
| | Blood Vessels | 1 | 2014 | 187 | 0.100 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 57 | 0.100 |
Why?
| | Spermatic Cord | 1 | 2012 | 1 | 0.100 |
Why?
| | Cohort Studies | 5 | 2016 | 5742 | 0.090 |
Why?
| | Creatinine | 1 | 2014 | 499 | 0.090 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 275 | 0.090 |
Why?
| | Autophagy | 1 | 2014 | 284 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 219 | 0.090 |
Why?
| | Radiation Dosage | 1 | 2013 | 179 | 0.090 |
Why?
| | Fetal Diseases | 1 | 2013 | 173 | 0.090 |
Why?
| | Surgical Wound Dehiscence | 1 | 2011 | 22 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 5472 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 855 | 0.090 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 71 | 0.090 |
Why?
| | Thrombectomy | 1 | 2011 | 69 | 0.080 |
Why?
| | Bevacizumab | 1 | 2011 | 138 | 0.080 |
Why?
| | Compliance | 1 | 2010 | 49 | 0.080 |
Why?
| | Texas | 1 | 2011 | 244 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2016 | 786 | 0.080 |
Why?
| | Sulfonamides | 1 | 2014 | 513 | 0.080 |
Why?
| | Rectum | 1 | 2011 | 185 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 530 | 0.080 |
Why?
| | Pyrroles | 1 | 2011 | 213 | 0.080 |
Why?
| | Internship and Residency | 1 | 2019 | 1147 | 0.080 |
Why?
| | Penis | 2 | 2019 | 36 | 0.080 |
Why?
| | Operative Time | 3 | 2014 | 145 | 0.080 |
Why?
| | Muscle, Smooth | 1 | 2010 | 155 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1062 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 786 | 0.080 |
Why?
| | Pilot Projects | 1 | 2014 | 1710 | 0.070 |
Why?
| | Radiography | 1 | 2011 | 822 | 0.070 |
Why?
| | Alleles | 1 | 2011 | 891 | 0.070 |
Why?
| | Remission, Spontaneous | 2 | 2021 | 40 | 0.070 |
Why?
| | MicroRNAs | 1 | 2014 | 692 | 0.070 |
Why?
| | Congenital Abnormalities | 1 | 2008 | 92 | 0.070 |
Why?
| | Indoles | 1 | 2011 | 412 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2031 | 0.070 |
Why?
| | Biomarkers | 2 | 2019 | 4149 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2012 | 570 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2014 | 3556 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2828 | 0.060 |
Why?
| | Pregnancy | 1 | 2018 | 6763 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5079 | 0.060 |
Why?
| | Cystoscopy | 2 | 2016 | 21 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 804 | 0.060 |
Why?
| | Nephroma, Mesoblastic | 1 | 2025 | 3 | 0.060 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2024 | 14 | 0.060 |
Why?
| | Image-Guided Biopsy | 1 | 2024 | 39 | 0.060 |
Why?
| | Adrenalectomy | 1 | 2024 | 68 | 0.060 |
Why?
| | Nephroureterectomy | 1 | 2023 | 2 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1430 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 280 | 0.050 |
Why?
| | Sexual Development | 1 | 2023 | 18 | 0.050 |
Why?
| | Gonads | 1 | 2023 | 23 | 0.050 |
Why?
| | Lymphoma | 1 | 2024 | 208 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 683 | 0.050 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 1000 | 0.050 |
Why?
| | Germany | 1 | 2020 | 121 | 0.040 |
Why?
| | Accreditation | 1 | 2019 | 83 | 0.040 |
Why?
| | Hyperplasia | 1 | 2019 | 175 | 0.040 |
Why?
| | Mohs Surgery | 1 | 2018 | 27 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 24 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2024 | 786 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2018 | 317 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 73 | 0.030 |
Why?
| | Ureteroscopy | 1 | 2016 | 18 | 0.030 |
Why?
| | Monitoring, Intraoperative | 1 | 2016 | 56 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 486 | 0.030 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 16 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2014 | 20 | 0.030 |
Why?
| | Ureterostomy | 1 | 2014 | 3 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 257 | 0.030 |
Why?
| | Oncogenes | 1 | 2014 | 116 | 0.030 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 3 | 0.030 |
Why?
| | Cicatrix | 1 | 2014 | 64 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 477 | 0.030 |
Why?
| | Mice, Nude | 1 | 2014 | 698 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 469 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2014 | 730 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2011 | 30 | 0.020 |
Why?
| | Pain, Postoperative | 1 | 2013 | 265 | 0.020 |
Why?
| | Area Under Curve | 1 | 2011 | 314 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2011 | 307 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1946 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2892 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 195 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 362 | 0.020 |
Why?
| | Dihydrolipoamide Dehydrogenase | 1 | 2009 | 7 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1396 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3412 | 0.020 |
Why?
|
|
Cost's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|